Event
FDA approves oral orforglipron (Foundayo)
Global · Regulatory
What to watch
Why variis flagged this
The first oral GLP-1 receptor agonist to clear the FDA.
Keep reading
Related coverage from the newsroom.
Every entity profile on variis is sourced. Not medical or investment advice.